Anja Engelke

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Journal: Future oncology (London, England)
Published: February 22, 2018

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Journal: The Lancet. Oncology
Published: January 26, 2018

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.

Journal: Drug design, development and therapy
Published: February 10, 2017

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Journal: Blood
Published: January 08, 2016

Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.

Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.

Journal: Leukemia
Published: December 23, 2015

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Journal: Blood
Published: June 17, 2015

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

Journal: Leukemia
Published: January 31, 2015

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Journal: The New England journal of medicine
Published: January 10, 2014

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.

Journal: Leukemia
Published: September 01, 2012
Showing 1-9 of 9

Last Updated: 09/26/2026